MiMedx stock: Surgical growth contrasts with a weaker third quarter

MiMedx Group reported third-quarter 2026 results on October 28, with the company describing a continued shift toward its Surgical franchise as the Wound business faces a difficult reimbursement environment. The results were reported by Morningstar, republishing a GlobeNewswire release.

Surgical growth meets reimbursement pressure

For the three months ended September 30, net sales were USD 62.283 million, down 45% from the prior-year quarter. Surgical sales rose 9% to USD 39.960 million, led by products including AMNIOFIX, AMNIOEFFECT and HELIOGEN. Management said Surgical volume increased in the mid-teens and now represents nearly two-thirds of company sales.

Wound sales fell 71% year over year to USD 22.323 million. MiMedx attributed the continued pressure to several Medicare reimbursement changes that took effect on January 1, 2026. Wound Care Center unit volume nevertheless increased 7% sequentially during the quarter, according to the company.

Margins improve as costs decline

Gross profit was USD 49.702 million, producing an 80% gross margin compared with 69% in the previous quarter and 84% a year earlier. Selling, general and administrative expenses declined to USD 58.313 million from USD 69.001 million in the prior-year period, although the company recorded strategic legal and transaction-related costs.

MiMedx posted a GAAP net loss of USD 8.683 million, or USD 0.06 per diluted share, compared with net income of USD 16.748 million a year earlier. Adjusted EBITDA, a non-GAAP measure, was USD 2.066 million. The figure excludes items including strategic legal and regulatory expenses, acquisition costs, share-based compensation and amortization.

Debt-free balance sheet and outlook

Cash and cash equivalents stood at USD 120.791 million on September 30. MiMedx repaid its remaining USD 17 million term loan during the quarter and ended the period with no debt outstanding. The balance sheet gives the company additional flexibility, but the sharp decline in Wound revenue remains a material operating issue.

MiMedx now expects 2026 net sales between USD 250 million and USD 260 million. It also expects fourth-quarter adjusted EBITDA to be higher sequentially and continues to target longer-term annual sales growth in the low double digits with an adjusted EBITDA margin above 20%. These are management targets and remain subject to reimbursement, regulatory and transaction risks.

In the broader US market, investors can follow developments through current S&P 500 market coverage.

For further company-specific coverage, see more news and analyses on MiMedx stock.